Linked Life Data

9509973

Source:http://linkedlifedata.com/resource/pubmed/id/9509973

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1998-6-1
pubmed:abstractText
Forty-nine patients with low-grade non-Hodgkin's lymphoma (NHL) received high-dose chemotherapy (HDC) with busulfan and cyclophosphamide (BUCY) or carmustine, etoposide, cytarabine and CY (BEAC) followed by unpurged autologous peripheral blood stem (PBSC) infusion. All patients had failed initial chemotherapy or progressed after an initial remission. Peripheral blood stem cells were mobilized with CY alone (n = 1), CY, etoposide (n = 19), or CY, etoposide and cisplatin (n = 29) followed by granulocyte colony-stimulating factor. Twenty-two patients received BU, 16 mg/kg, and CY, 120 mg/kg. Twenty-seven patients received carmustine 300 mg/m2, etoposide 600 mg/m2, cytarabine 600 mg/m2, and CY 140 mg/kg. Four patients (8%) died of non-relapse causes, two (9%) in the BUCY group and two (7%) in the BEAC group. Twenty-seven patients (55%) relapsed or progressed at a median of 9.4 months (2-38) from PBSC infusion. Ten patients who relapsed are alive a median of 31 months (range, 6-47) after relapse. The probabilities of relapse at 3.6 years for patients receiving BUCY or BEAC were 0.57 and 0.70, respectively (P = 0.92). Twenty-seven patients (55%) are alive at a median of 3.6 years (range, 1-5). The probabilities of survival at 3.6 years for patients receiving BUCY or BEAC were 0.58 and 0.55, respectively (P = 0.72). The probabilities of EFS at 3.6 years for patients receiving BUCY or BEAC were 0.36 and 0.28, respectively (P = 0.82). It was concluded that BUCY is an active regimen for the treatment of patients with low-grade NHL.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
383-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:9509973-Adult, pubmed-meshheading:9509973-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9509973-Busulfan, pubmed-meshheading:9509973-Carmustine, pubmed-meshheading:9509973-Combined Modality Therapy, pubmed-meshheading:9509973-Cyclophosphamide, pubmed-meshheading:9509973-Cytarabine, pubmed-meshheading:9509973-Etoposide, pubmed-meshheading:9509973-Female, pubmed-meshheading:9509973-Graft Survival, pubmed-meshheading:9509973-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:9509973-Humans, pubmed-meshheading:9509973-Lymphoma, Non-Hodgkin, pubmed-meshheading:9509973-Male, pubmed-meshheading:9509973-Middle Aged, pubmed-meshheading:9509973-Recurrence, pubmed-meshheading:9509973-Survival Rate, pubmed-meshheading:9509973-Transplantation, Autologous
pubmed:year
1998
pubmed:articleTitle
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
pubmed:affiliation
Clinical Research Division of Response Oncology, Inc, Memphis, TN 98122, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial, Multicenter Study